Estrogen receptor (ER) status directly correlates with IGFBP2 expression in breast cancer, with ER-positive cancers having higher levels of IGFBP2 than ER-negative cancers (80, 101, 102), and therefore the high levels of IGFBP2 may simply reflect a functional ER pathway. Here, IGFBP2 is linked to breast carcinoma.